Background: Several severity scoring systems have been proposed for skin and soft tissue infections (SSTIs), but none has been tested prospectively.
Introduction
Skin and soft tissue infections (SSTIs) are the second most common indication for inpatient antimicrobial therapy in European hospitals. 1 In a retrospective study, which recruited from all hospital wards and included hospital-acquired infections, we showed that empirical therapy was not evidence based, with significant under-treatment of severely ill patients. 2 The aim of the present study was to prospectively identify patients with SSTIs presenting from the community, to document clinical management, illness severity, and outcome.
Methods
The cohort was enrolled from acute medical admissions in two hospitals (one teaching and one District General) in Tayside, Scotland between April 2009 and June 2010. Convenience sampling was based on the data collector's (N. R.) availability, which included weekend days. Potential cases were identified from admission lists. Adult patients (≥18 years old) with a primary diagnosis of SSTI (cellulitis, erysipelas or necrotizing fasciitis) who received antimicrobials were enrolled. Patients with a primary diagnosis of abscess, where drainage is the principal treatment, were excluded.
Clinical details were extracted from the case records. The study adverse outcomes were death within 30 days and re-admission to hospital within 2 weeks of discharge. Outcome data were obtained from the National Register and the Scottish Morbidity Record. Severity was assessed with a modified version 2 of the classification in a UK guideline [the Clinical Resource Efficiency Support Team (CREST) guidelines] for the management of cellulitis in adults. 3 Classification of severity by these modified CREST criteria incorporates the standardized early warning system (SEWS) score, which is calculated routinely on nursing observations charts and is designed to identify patients at risk of deterioration.
# The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2012; 67: 1016 -1019 doi:10.1093/jac/dkr554 Advance Access publication 9 January 2012 Severity by CREST criteria was compared with severity by criteria proposed by Ki and Rotstein. 4 The Ki/Rotstein criteria stratify patients as 'mild' or 'moderate/severe' based on comorbidity, physiological parameters, the anatomical site and size of the affected area and the presence or absence of features suggesting necrotizing fasciitis. 4 The initial choice of antimicrobial therapy was compared with therapy recommended in the Tayside Formulary, based on the CREST guideline. 3 For each case, two independent reviewers (N. R. and C. M.) rated the appropriateness of therapy, and inter-rater reliability was assessed.
The case definitions and criteria for appropriate treatment by CREST class were: class I, no recorded relevant comorbidity (peripheral vascular disease, chronic venous insufficiency or morbid obesity), no sepsis and SEWS ,4-oral therapy active against Streptococcus pyogenes and Staphylococcus aureus; class II, relevant comorbidity, no sepsis and SEWS ,4-intravenous therapy active against S. pyogenes and S. aureus; class III, sepsis and SEWS ,4-intravenous therapy active against S. pyogenes and S. aureus; and class IV, sepsis and SEWS ≥4-intravenous therapy active against S. pyogenes, S. aureus, Gram-negative organisms, anaerobes and their toxins.
Variables were summarized using proportions, and medians with IQRs. Comparisons were by ORs with 95% CIs. Inter-rater agreement was assessed by percentage agreement and the kappa statistic. The significance of any differences in adverse outcome by demographic variable (age, gender, comorbidity), management (appropriate antibiotics, antibiotics within 4 h) or severity classification (CREST, Ki/Rotstein) was tested using Fisher's exact test. Analysis was performed in Microsoft Excel 2007 and SPSS Statistics 17.0.
The Local Research Ethics Committee deemed formal committee review of the study unnecessary. The study protocol was approved by the Caldicott Guardian for hospital inpatients.
Results
Admissions lists on 160 days were screened, and 79 patients were enrolled on 73 separate days. The median age was 52 years (IQR 37-69) and 65% were male. Most (86%) patients had infection involving a limb, and around half were in the less severe CREST categories on admission (Table 1 ). There were significant disagreements between the CREST and Ki/Rotstein severity classifications for 21 (27%) patients: 14 in CREST class I were classed as moderate/severe by the Ki/Rotstein criteria, and seven Table 1 . Demography, blood cultures, clinical environment and monitoring by CREST class on admission CREST class on admission Management of acute medical admissions with SSTI patients with sepsis (CREST class III) were classed as mild (Ki/ Rotstein) and suitable for outpatient treatment. (Table 1) . Invasive monitoring/support and surgical intervention increased with severity class (Table 1) . Five (45%) of the CREST class IV patients were treated in a Critical Care Unit. One patient in CREST class I on admission deteriorated to CREST class IV the same day and was admitted to the Intensive Care Unit. Overall, using the worst, rather than the initial, set of clinical observations in the 24 h from admission, 15/79 (19%) patients were reclassified into a more severe CREST category (Table 2) .
Blood cultures were taken from 66% of patients, including 56% in CREST classes I and II. Positive blood cultures were more likely in CREST classes III and IV versus I and II (24% versus 4%, OR 7.00, 95% CI 0.79 -61.74). The organisms isolated were S. pyogenes (3 patients), methicillin-susceptible S. aureus (2 patients), group B Streptococcus (1 patient), Pseudomonas aeruginosa (1 patient) and Clostridium septicum (1 patient).
The two raters agreed on the appropriateness of initial antimicrobial therapy in 77/79 (97%) cases [kappa¼0.94 (95% CI 0.86-1.00), P,0.01], with the two cases of disagreement being simple error by one rater. Overall, treatment was deemed appropriate in 30% of cases (Table 2) .
Over-treatment was common in the less severe classes (89% and 75% for classes I and II, respectively) with 33/37 (89%) patients in class I receiving intravenous treatment (Table 2) . Under-treatment was common in the more severe classes. In class IV, only 1/11 (9%) patient received appropriate broadspectrum antimicrobials (co-amoxiclav, flucloxacillin and clindamycin), 7/11 (64%) patients had no Gram-negative therapy, and 5/11 received flucloxacillin alone. Overall, using the worst set of clinical observations in the first 24 h, rather than the initial set, increased the proportion of under-treated patients from 13% to 22% (Table 2) .
Most patients [63/79 (80%)] received antimicrobials within 4 h of admission, but this was no more likely in classes III and IV [30/38 (79%)] than in classes I and II [33/41 (81%)]. Of patients in class IV on admission, only 2/11 (18%) received antimicrobials within the 1 h target for severe sepsis.
Within 30 days of admission two patients died, and three were re-admitted within 2 weeks of discharge, meaning five (6%) patients had adverse outcomes. The patients who died were both over 70 years old, but without documented comorbidity. One was in each of CREST classes III and IV, and both were classed as moderate/severe by the Ki/Rotstein criteria. Initial antibiotic therapy was appropriate, but very delayed (9 h from admission) in one case, and prompt (65 min) but inappropriate in the other.
Validation of the severity scores was impossible given the small number of adverse outcomes. Analysis of outcome by demographic and clinical variables found that the only significant difference in adverse outcomes was between those who received antibiotics within 4 h of admission [2/61 (3%)] and those who did not [3/13 (23%); Fisher's exact test P ¼ 0.05].
Discussion
This is, to our knowledge, the first prospective study of severity stratification and management of community-acquired SSTIs of patients enrolled on hospital admission. Other published studies have been retrospective, with patients identified from databases or ICD-10 (International Classification of Diseases, Tenth Revision) discharge codes. 2,5 -7 Our results show that community-acquired SSTIs are a frequent reason for hospital admission, with 1 new patient every 2 days in Tayside (population 350000). 8 As in previous studies, 2,5 -7 we found evidence of overtreatment of mild infections and under-treatment of severe infections. This highlights uncertainty regarding appropriate antimicrobial treatment of SSTIs. Two of our findings might help explain some of this uncertainty. Firstly, there were significant discrepancies between two published severity criteria (Table 1) . Secondly, observations on admission to hospital underestimated the severity of infection in 19% of patients, consistent with a recent study of sepsis identification in Acute Medical Units, which found a median time from admission to highest sepsis score of 152 min (IQR 71-284 min). 9 As in our previous study 2 and a recent study from the USA, 5 we found high prevalence of wasteful investigation and management in patients without sepsis. CREST guidelines recommend blood cultures only in classes III and IV.
3 Unnecessary blood culture Marwick et al.
wastes laboratory resources, and contamination may prolong hospitalization and the use of intravenous antimicrobials. The strengths of this study included prospective design, ensuring the appropriate primary diagnosis for enrolment, and ensuring that there was no sampling bias. It also ensured that patients presented with true community-acquired SSTIs. Enrolment through multiple acute medical/emergency assessment areas provided an unselected cohort of adults with complete spectra of age, comorbidity, site of infection and illness severity.
Significant weaknesses of the study are the small study population and the very small number of adverse outcome events, which precluded assessment of the validity of the severity scores. Our results show potentially important discrepancies between two published severity scores (Table 1 ).
In the absence of evidence from large prospective studies about the added value of complex, specific SSTI severity scores over generic sepsis scores, we have simplified the Tayside Antibiotic Policy for SSTI by classifying into three levels of severity: no sepsis, sepsis, and severe sepsis/necrotizing fasciitis. In the Acute Medicine Unit we are advocating the use of Sepsis Six 10 for all patients with sepsis, regardless of source. We are also emphasizing the need to reassess acute medical admissions with infection because observations on admission may underestimate severity. 9 
